Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer

Christopher J. Sweeney, Chris H. Takimoto, Jane E. Latz, Sharyn D. Baker, Daryl J Murry, James H. Krull, Karen Fife, Linda Battiato, Ann Cleverly, Ajai K. Chaudhary, Tuhin Chaudhuri, Alan Sandler, Alain C. Mita, Eric K. Rowinsky

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Purpose: Pemetrexed is an antimetabolite that is structurally similar to methotrexate. Because nonsteroidal anti-inflammatory drugs (NSAID) impair methotrexate clearance and increase its toxicity, we evaluated the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in advanced cancer patients. Experimental Design: In two independent, randomized, crossover drug interaction studies, cancer patients with a creatinine clearance (CrCl) ≥60 mL/min received an NSAID (aspirin or ibuprofen) with either the first or the second dose of pemetrexed (cycle 1 or 2). Pemetrexed (500 mg/m2) was infused i.v. on day 1 of a 21-day cycle, and all patients were supplemented with oral folic acid and i.m. vitamin B12. Aspirin (325 mg) or ibuprofen (400 mg; 2 × 200 mg) was given orally every 6 hours, starting 2 days before pemetrexed administration, with the ninth and final dose taken 1 hour before infusion. Pemetrexed pharmacokinetics with and without concomitant NSAID treatment were compared for cycles 1 and 2. Results: Data from 27 patients in each study were evaluable for the analysis of pemetrexed pharmacokinetics. Coadministration of aspirin did not alter pemetrexed pharmacokinetics; however, ibuprofen coadministration was associated with a 16% reduction in clearance, a 15% increase in maximum plasma concentration, and a 20% increase in area under the plasma concentration versus time curve but no significant change in Vss compared with pemetrexed alone. No febrile neutropenia occurred in any patient, and no increase in pemetrexed-related toxicity was associated with NSAID administration. Conclusions: Pemetrexed (500 mg/m2) with vitamin supplementation is well tolerated and requires no dosage adjustment when coadministered with aspirin (in patients with CrCl ≥60 mL/min) or ibuprofen (in patients with CrCl ≥80 mL/min).

Original languageEnglish (US)
Pages (from-to)536-542
Number of pages7
JournalClinical Cancer Research
Volume12
Issue number2
DOIs
StatePublished - Jan 15 2006

Fingerprint

Pemetrexed
Ibuprofen
Drug Interactions
Aspirin
Pharmacokinetics
Neoplasms
Anti-Inflammatory Agents
Creatinine
Methotrexate
Pharmaceutical Preparations
Antimetabolites
Febrile Neutropenia
Vitamin B 12

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. / Sweeney, Christopher J.; Takimoto, Chris H.; Latz, Jane E.; Baker, Sharyn D.; Murry, Daryl J; Krull, James H.; Fife, Karen; Battiato, Linda; Cleverly, Ann; Chaudhary, Ajai K.; Chaudhuri, Tuhin; Sandler, Alan; Mita, Alain C.; Rowinsky, Eric K.

In: Clinical Cancer Research, Vol. 12, No. 2, 15.01.2006, p. 536-542.

Research output: Contribution to journalArticle

Sweeney, CJ, Takimoto, CH, Latz, JE, Baker, SD, Murry, DJ, Krull, JH, Fife, K, Battiato, L, Cleverly, A, Chaudhary, AK, Chaudhuri, T, Sandler, A, Mita, AC & Rowinsky, EK 2006, 'Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer', Clinical Cancer Research, vol. 12, no. 2, pp. 536-542. https://doi.org/10.1158/1078-0432.CCR-05-1834
Sweeney, Christopher J. ; Takimoto, Chris H. ; Latz, Jane E. ; Baker, Sharyn D. ; Murry, Daryl J ; Krull, James H. ; Fife, Karen ; Battiato, Linda ; Cleverly, Ann ; Chaudhary, Ajai K. ; Chaudhuri, Tuhin ; Sandler, Alan ; Mita, Alain C. ; Rowinsky, Eric K. / Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 2. pp. 536-542.
@article{8315bebebbdf4e499ae8604e19064cfd,
title = "Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer",
abstract = "Purpose: Pemetrexed is an antimetabolite that is structurally similar to methotrexate. Because nonsteroidal anti-inflammatory drugs (NSAID) impair methotrexate clearance and increase its toxicity, we evaluated the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in advanced cancer patients. Experimental Design: In two independent, randomized, crossover drug interaction studies, cancer patients with a creatinine clearance (CrCl) ≥60 mL/min received an NSAID (aspirin or ibuprofen) with either the first or the second dose of pemetrexed (cycle 1 or 2). Pemetrexed (500 mg/m2) was infused i.v. on day 1 of a 21-day cycle, and all patients were supplemented with oral folic acid and i.m. vitamin B12. Aspirin (325 mg) or ibuprofen (400 mg; 2 × 200 mg) was given orally every 6 hours, starting 2 days before pemetrexed administration, with the ninth and final dose taken 1 hour before infusion. Pemetrexed pharmacokinetics with and without concomitant NSAID treatment were compared for cycles 1 and 2. Results: Data from 27 patients in each study were evaluable for the analysis of pemetrexed pharmacokinetics. Coadministration of aspirin did not alter pemetrexed pharmacokinetics; however, ibuprofen coadministration was associated with a 16{\%} reduction in clearance, a 15{\%} increase in maximum plasma concentration, and a 20{\%} increase in area under the plasma concentration versus time curve but no significant change in Vss compared with pemetrexed alone. No febrile neutropenia occurred in any patient, and no increase in pemetrexed-related toxicity was associated with NSAID administration. Conclusions: Pemetrexed (500 mg/m2) with vitamin supplementation is well tolerated and requires no dosage adjustment when coadministered with aspirin (in patients with CrCl ≥60 mL/min) or ibuprofen (in patients with CrCl ≥80 mL/min).",
author = "Sweeney, {Christopher J.} and Takimoto, {Chris H.} and Latz, {Jane E.} and Baker, {Sharyn D.} and Murry, {Daryl J} and Krull, {James H.} and Karen Fife and Linda Battiato and Ann Cleverly and Chaudhary, {Ajai K.} and Tuhin Chaudhuri and Alan Sandler and Mita, {Alain C.} and Rowinsky, {Eric K.}",
year = "2006",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-05-1834",
language = "English (US)",
volume = "12",
pages = "536--542",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer

AU - Sweeney, Christopher J.

AU - Takimoto, Chris H.

AU - Latz, Jane E.

AU - Baker, Sharyn D.

AU - Murry, Daryl J

AU - Krull, James H.

AU - Fife, Karen

AU - Battiato, Linda

AU - Cleverly, Ann

AU - Chaudhary, Ajai K.

AU - Chaudhuri, Tuhin

AU - Sandler, Alan

AU - Mita, Alain C.

AU - Rowinsky, Eric K.

PY - 2006/1/15

Y1 - 2006/1/15

N2 - Purpose: Pemetrexed is an antimetabolite that is structurally similar to methotrexate. Because nonsteroidal anti-inflammatory drugs (NSAID) impair methotrexate clearance and increase its toxicity, we evaluated the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in advanced cancer patients. Experimental Design: In two independent, randomized, crossover drug interaction studies, cancer patients with a creatinine clearance (CrCl) ≥60 mL/min received an NSAID (aspirin or ibuprofen) with either the first or the second dose of pemetrexed (cycle 1 or 2). Pemetrexed (500 mg/m2) was infused i.v. on day 1 of a 21-day cycle, and all patients were supplemented with oral folic acid and i.m. vitamin B12. Aspirin (325 mg) or ibuprofen (400 mg; 2 × 200 mg) was given orally every 6 hours, starting 2 days before pemetrexed administration, with the ninth and final dose taken 1 hour before infusion. Pemetrexed pharmacokinetics with and without concomitant NSAID treatment were compared for cycles 1 and 2. Results: Data from 27 patients in each study were evaluable for the analysis of pemetrexed pharmacokinetics. Coadministration of aspirin did not alter pemetrexed pharmacokinetics; however, ibuprofen coadministration was associated with a 16% reduction in clearance, a 15% increase in maximum plasma concentration, and a 20% increase in area under the plasma concentration versus time curve but no significant change in Vss compared with pemetrexed alone. No febrile neutropenia occurred in any patient, and no increase in pemetrexed-related toxicity was associated with NSAID administration. Conclusions: Pemetrexed (500 mg/m2) with vitamin supplementation is well tolerated and requires no dosage adjustment when coadministered with aspirin (in patients with CrCl ≥60 mL/min) or ibuprofen (in patients with CrCl ≥80 mL/min).

AB - Purpose: Pemetrexed is an antimetabolite that is structurally similar to methotrexate. Because nonsteroidal anti-inflammatory drugs (NSAID) impair methotrexate clearance and increase its toxicity, we evaluated the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in advanced cancer patients. Experimental Design: In two independent, randomized, crossover drug interaction studies, cancer patients with a creatinine clearance (CrCl) ≥60 mL/min received an NSAID (aspirin or ibuprofen) with either the first or the second dose of pemetrexed (cycle 1 or 2). Pemetrexed (500 mg/m2) was infused i.v. on day 1 of a 21-day cycle, and all patients were supplemented with oral folic acid and i.m. vitamin B12. Aspirin (325 mg) or ibuprofen (400 mg; 2 × 200 mg) was given orally every 6 hours, starting 2 days before pemetrexed administration, with the ninth and final dose taken 1 hour before infusion. Pemetrexed pharmacokinetics with and without concomitant NSAID treatment were compared for cycles 1 and 2. Results: Data from 27 patients in each study were evaluable for the analysis of pemetrexed pharmacokinetics. Coadministration of aspirin did not alter pemetrexed pharmacokinetics; however, ibuprofen coadministration was associated with a 16% reduction in clearance, a 15% increase in maximum plasma concentration, and a 20% increase in area under the plasma concentration versus time curve but no significant change in Vss compared with pemetrexed alone. No febrile neutropenia occurred in any patient, and no increase in pemetrexed-related toxicity was associated with NSAID administration. Conclusions: Pemetrexed (500 mg/m2) with vitamin supplementation is well tolerated and requires no dosage adjustment when coadministered with aspirin (in patients with CrCl ≥60 mL/min) or ibuprofen (in patients with CrCl ≥80 mL/min).

UR - http://www.scopus.com/inward/record.url?scp=31544476910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544476910&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-1834

DO - 10.1158/1078-0432.CCR-05-1834

M3 - Article

VL - 12

SP - 536

EP - 542

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -